Analysts think QNCX stock price could increase by 6668%
Jul 31, 2024, 6:26 AM
-5.50%
What does QNCX do
Quince Therapeutics, headquartered in South San Francisco, focuses on developing EryDex for Ataxia-Telangiectasia using their AIDE technology for optimal drug delivery. Since their IPO on 2019-05-09, they aim to expand the platform’s applications beyond rare diseases.
4 analysts think QNCX stock price will increase by 6668.10%. The current median analyst target is $50.49 compared to a current stock price of $0.75. The lowest analysts target is $3.03 and the highest analyst target is $100.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.